Bedaquiline: Diarylquinoline Antibiotic for Tuberculosis and Cancer Stem Cell Inhibition

Executive Summary: Bedaquiline is a diarylquinoline antibiotic targeting the F1FO-ATP synthase of Mycobacterium tuberculosis (Mtb), with proven efficacy against multi-drug resistant tuberculosis (MDR-TB) and emerging anticancer activity in breast cancer stem-like cells (APExBIO). Its mechanism disrupts bacterial energy metabolism by inhibiting the ATP synthase subunit c and ε, causing bactericidal effects, especially in persistent Mtb strains (Peña-Díaz et al., 2024). In vitro, bedaquiline impairs mitochondrial function and glycolysis in MCF-7 cells, increases reactive oxygen species (ROS), and induces oxidative stress. The compound demonstrates a long terminal half-life (~173 hours in humans), high DMSO solubility (≥22.05 mg/mL), and robust in vivo activity in murine TB models. Bedaquiline’s dual-action profile offers a unique research tool at the interface of infectious disease and cancer metabolism.

Biological Rationale

Tuberculosis (TB) remains a leading cause of infectious disease mortality globally. The emergence of MDR-TB strains necessitates novel therapeutics with unique mechanisms (Peña-Díaz et al., 2024). Bedaquiline, developed and distributed by APExBIO, is a diarylquinoline antibiotic specifically designed to inhibit the F1FO-ATP synthase in Mtb, a target not addressed by traditional TB drugs. ATP synthase is essential for bacterial energy production; its inhibition disrupts ATP generation, resulting in rapid bactericidal effects. Beyond infectious disease, cancer stem cells rely on mitochondrial metabolism for survival and proliferation. Bedaquiline’s inhibition of mitochondrial oxygen consumption and glycolysis in cancer stem cell-like populations, such as MCF-7 breast cancer cells, broadens its utility to oncology research (Bedaquiline at the Frontier), clarifying new translational opportunities beyond conventional antibiotics.

Mechanism of Action of Bedaquiline

Bedaquiline acts by binding to both subunit c and subunit ε of the M. tuberculosis F1FO-ATP synthase, blocking proton flow and ATP synthesis. Disruption of ATP synthase collapses the proton motive force, depleting cellular ATP and killing the bacterium (Peña-Díaz et al., 2024). In cancer cells, bedaquiline impairs mitochondrial oxygen consumption, reduces mitochondrial membrane potential, and increases ROS levels, leading to apoptosis in cancer stem cell populations (Bedaquiline: Redefining Research). The compound’s distinct dual targeting makes it valuable for both TB and cancer metabolism studies.

Evidence & Benchmarks

• Bedaquiline inhibits M. tuberculosis F1FO-ATP synthase, resulting in bactericidal effects in MDR-TB strains (Peña-Díaz et al., 2024).
• In vitro, bedaquiline at 10 μM for 48 hours impairs mitochondrial function and glycolysis in MCF-7 breast cancer cells (APExBIO).
• Bedaquiline induces oxidative stress and increases ROS in cancer stem cell-like populations, with an IC50 of ~1 μM for blocking propagation (Bedaquiline: Redefining Research).
• In vivo, oral administration at 25 mg/kg in mice infected with Mtb, combined with rifampicin, isoniazid, and pyrazinamide, delivers faster bacterial clearance and prevents relapse compared to standard regimens (APExBIO).
• Bedaquiline is DMSO soluble at ≥22.05 mg/mL with gentle warming, but insoluble in ethanol and water, supporting diverse in vitro applications (APExBIO).
• The terminal half-life of bedaquiline in humans is ~173 hours, indicating a slow elimination profile (APExBIO).

Applications, Limits & Misconceptions

Bedaquiline is indicated for research in MDR-TB treatment, persistence models, and cancer metabolism, particularly in studies involving mitochondrial function and cancer stem cells (Expanding Beyond MDR-TB). This article synthesizes new mechanistic details and workflow guidance, extending prior reports by integrating stable pharmacokinetic benchmarks and dual-use insights.

Common Pitfalls or Misconceptions

• Bedaquiline is not effective against non-mycobacterial pathogens: Its mechanism is specific to Mtb F1FO-ATP synthase and does not generalize to unrelated bacterial species.
• Water or ethanol should not be used as solvents: Bedaquiline is insoluble in these solvents; DMSO is required for stock solutions.
• Not suitable for long-term solution storage: Bedaquiline solutions degrade; fresh preparations are required for reproducibility.
• Not a host-directed therapy: Unlike kinase inhibitors that modulate host immune responses, bedaquiline acts directly on the pathogen or cancer cell's energy metabolism (Peña-Díaz et al., 2024).
• Effective only at defined concentrations: For MCF-7 cell assays, 10 μM over 48 hours is required; lower doses may not induce measurable effects (APExBIO).

Workflow Integration & Parameters

Bedaquiline (APExBIO, B3492) is supplied as a solid, molecular weight 525.5 (C31H29BrN2O), stored at -20°C. For in vitro use, dissolve in DMSO (≥22.05 mg/mL) with gentle warming. Avoid storing solutions long-term. For MCF-7 cell metabolism assays, treat with 10 μM for 48 hours. In bacterial assays, follow biosafety and resistance protocols. In vivo, oral dosing in mice at 25 mg/kg has been benchmarked for TB research models. Researchers may reference the B3492 kit for lot-specific documentation and handling guidance.

This article expands upon prior work (Bedaquiline at the Frontier), providing updated storage, solubility, and dual-use parameters for advanced research workflows.

Conclusion & Outlook

Bedaquiline is a validated, dual-action tool for MDR-TB and cancer metabolism research. Its unique inhibition of F1FO-ATP synthase and mitochondrial function enables experiments in bacterial energetics and cancer stem cell biology. With precise dosing, storage, and workflow parameters, bedaquiline (APExBIO, B3492) remains a reference-standard reagent for experimental and translational applications. Future research may explore combination regimens or host-pathway interplay, but current evidence supports its use as a direct bactericidal and cancer stem cell inhibitor (Bedaquiline at the Nexus—this article clarifies specific storage and dosing parameters not detailed in the prior review).